硼替唑米治疗多发性骨髓瘤异基因移植后慢性移植物抗宿主病:一举两得  

Bortezomib therapy for cGVHD after allo-stem cell transplantation for multiple myeloma patient:kill two birds with one stone

作　　者：李增军[1] 邹德慧[1] 邱录贵[1] 

机构地区：[1]中国医学科学院北京协和医学院血液学研究所血液病医院,天津300020

出　　处：《临床血液学杂志》2011年第4期394-396,共3页Journal of Clinical Hematology

基　　金：国家科技支撑计划项目(No:2008BAI61B01);天津市科技支撑计划项目(No:09ZCGYSF01000)

摘　　要：目的:探讨硼替佐米治疗多发性骨髓瘤异基因移植后移植物抗宿主病(GVHD)及原发病的双重作用。方法:报道1例异基因移植后发生慢性难治性GVHD、同时可疑复发的多发性骨髓瘤患者应用硼替佐米后的效果;同时对硼替佐米治疗GVHD的文献进行复习。结果:应用硼替佐米后患者慢性GVHD获得部分治疗反应,同时巩固了原发病的疗效。文献报道也支持硼替佐米对GVHD的防治作用。结论:硼替佐米可同时治疗骨髓瘤异基因移植后的GVHD和原发病,值得进一步探讨。Objective：To explore the dual function of bortezomib on multiple myeloma（MM） itself and on graft versus host disease（GVHD） after allo-stem cell transplantation.Method：A case of MM patient,who suffered from refractory chronic graft versus host disease（cGVHD） after allo-stem cell transplantation and unconfirmed recurrence of MM,was treated with bortezomib.The documents about the role of bortezomib on GVHD were reviewed briefly.Result：Partial response was achieved on cGVHD and the primary disease was consolidated with the therapy of bortezomib.The documents supported the use of bortezomib on the prevention and therapy of GVHD.Conclusion：Bortezomib may provide an effective therapy on GVHD especially for MM patients with the additional benefit on myeloma itself.

关 键 词：多发性骨髓瘤 硼替唑米 异基因移植 移植物抗宿主病 

分 类 号：R733.3[医药卫生—肿瘤]